

# **Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019**

<https://marketpublishers.com/r/TB306DB9C66EN.html>

Date: April 2019

Pages: 85

Price: US\$ 3,500.00 (Single User License)

ID: TB306DB9C66EN

## **Abstracts**

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019

### **SUMMARY**

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds

to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 5 and 8 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Gastrointestinal, Immunology and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer, Cervical Cancer, Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Lung Cancer, Metastatic Melanoma, Renal Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Esophageal Cancer, Follicular Lymphoma, Hepatitis B, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Ocular Melanoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes), Ulcerative Colitis and Uterine Cancer.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development

AbbVie Inc

Abeome Corp

Alligator Bioscience AB

Apogenix AG

BioInvent International AB

Bristol-Myers Squibb Co

Denceptor Therapeutics Ltd

GigaGen Inc

GlaxoSmithKline Plc

Incyte Corp

Innovent Biologics Inc

Invenra Inc

Johnson & Johnson

Kyowa Hakko Kirin Co Ltd

Pfizer Inc

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles

ABBV-368 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABM-193 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATOR-1015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Agonize FCGR2A, FCGR2B and TNFRSF4 for Methicillin-Resistant Staphylococcus aureus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Agonize TNFRSF4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize OX40 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3174998 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HuOHX-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBI-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-1949 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KHK-4083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40L Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize OX40 for Hematological Tumor and Solid Tumor -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize OX40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OrthomAb - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04518600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCB-340 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-279252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones

Featured News & Press Releases

Apr 11, 2019: Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer

Apr 10, 2019: Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston

Mar 07, 2019: Alligator Bioscience: First patient dosed in phase I study of ATOR-1015

Feb 20, 2019: GigaGen Publishes Study Demonstrating Optimal Method for Selecting

*Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycopro...*



## OX40 Therapeutic Candidates from Antibody Repertoires

Feb 14, 2019: Innovent starts treatment in IBI101 monoclonal antibody trial

Dec 11, 2018: Alligator Bioscience starts clinical phase I study with ATOR-1015

Dec 04, 2018: Innovent receives an approval from the US FDA to initiate clinical trials for its Anti-OX40 Monoclonal Antibody IBI101

Jul 25, 2018: Innovent receives IND approval to initiate clinical trials in china with its anti-OX40 Agonistic Antibody IBI101

Jul 19, 2018: Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody

Apr 17, 2018: Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation

Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015

Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4

Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019  
Number of Products under Development by Therapy Areas, H1 2019  
Number of Products under Development by Indications, H1 2019  
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019  
Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019  
Number of Products under Development by Companies, H1 2019  
Number of Products under Development by Companies, H1 2019 (Contd..1)  
Products under Development by Companies, H1 2019  
Products under Development by Companies, H1 2019 (Contd..1), H1 2019  
Products under Development by Companies, H1 2019 (Contd..2), H1 2019  
Products under Development by Companies, H1 2019 (Contd..3), H1 2019  
Products under Development by Companies, H1 2019 (Contd..4), H1 2019  
Products under Development by Companies, H1 2019 (Contd..5), H1 2019  
Number of Products under Investigation by Universities/Institutes, H1 2019  
Products under Investigation by Universities/Institutes, H1 2019  
Number of Products by Stage and Mechanism of Actions, H1 2019  
Number of Products by Stage and Route of Administration, H1 2019  
Number of Products by Stage and Molecule Type, H1 2019  
Pipeline by AbbVie Inc, H1 2019  
Pipeline by Abeome Corp, H1 2019  
Pipeline by Alligator Bioscience AB, H1 2019  
Pipeline by Apogenix AG, H1 2019  
Pipeline by BioInvent International AB, H1 2019  
Pipeline by Bristol-Myers Squibb Co, H1 2019  
Pipeline by Denceptor Therapeutics Ltd, H1 2019  
Pipeline by GigaGen Inc, H1 2019  
Pipeline by GlaxoSmithKline Plc, H1 2019  
Pipeline by Incyte Corp, H1 2019  
Pipeline by Innovent Biologics Inc, H1 2019  
Pipeline by Invenra Inc, H1 2019  
Pipeline by Johnson & Johnson, H1 2019  
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2019  
Pipeline by Pfizer Inc, H1 2019  
Dormant Projects, H1 2019  
Discontinued Products, H1 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019  
Number of Products under Development by Therapy Areas, H1 2019  
Number of Products under Development by Top 10 Indications, H1 2019  
Number of Products by Mechanism of Actions, H1 2019  
Number of Products by Stage and Mechanism of Actions, H1 2019  
Number of Products by Routes of Administration, H1 2019  
Number of Products by Stage and Routes of Administration, H1 2019  
Number of Products by Molecule Types, H1 2019  
Number of Products by Stage and Molecule Types, H1 2019

### COMPANIES MENTIONED

AbbVie Inc  
Abeome Corp  
Alligator Bioscience AB  
Apogenix AG  
BioInvent International AB  
Bristol-Myers Squibb Co  
Denceptor Therapeutics Ltd  
GigaGen Inc  
GlaxoSmithKline Plc  
Incyte Corp  
Innovent Biologics Inc  
Invenra Inc  
Johnson & Johnson  
Kyowa Hakko Kirin Co Ltd  
Pfizer Inc

## I would like to order

Product name: Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019

Product link: <https://marketpublishers.com/r/TB306DB9C66EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TB306DB9C66EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970